Egrifta (Tesamorelin) vs AOD-9604: When to Pick One, the Other, or the Stack

What These Two Peptides Actually Do

Tesamorelin and AOD-9604 both affect body fat, but through different pathways. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It stimulates your pituitary to release growth hormone in a pulse-like pattern, which then drives IGF-1 production and ultimately shifts your metabolism toward fat oxidation, with the strongest clinical signal at visceral adipose tissue. AOD-9604 is a 16-amino-acid fragment of the C-terminal end of human growth hormone (residues 176-191). It is thought to stimulate fat breakdown and inhibit fat storage through a mechanism that does not require IGF-1 as an intermediary.

The distinction matters for you as a woman because IGF-1 has downstream effects on the menstrual cycle, insulin sensitivity, and potentially hormone-sensitive tissue. An agent that raises GH and IGF-1 (tesamorelin) carries different considerations across your reproductive lifespan than one that may act more peripherally (AOD-9604).

How Tesamorelin Works in the Body

Tesamorelin binds pituitary GHRH receptors and triggers pulsatile GH release. In the LIPO-010 Phase III trial, 26 weeks of tesamorelin 2 mg daily reduced visceral adipose tissue (VAT) by a mean of 18% versus placebo in adults with HIV-associated lipodystrophy, a population that is predominantly male. IGF-1 rises roughly 80-100 ng/mL above baseline at the approved 1 mg dose, and this IGF-1 elevation is measurable within four weeks of starting therapy.

Because GH itself is anabolic and affects insulin signaling, tesamorelin can transiently reduce insulin sensitivity, a point examined further in the perimenopause section below.

How AOD-9604 Works in the Body

AOD-9604 was originally developed by Metabolic Pharmaceuticals in Australia as an anti-obesity drug candidate. In rodent studies published in the American Journal of Physiology, the fragment reduced body weight and fat mass in obese mice without affecting blood glucose or IGF-1. A small human pilot study (n = 300) conducted by the same group showed dose-dependent fat loss at 1 mg/day oral dosing, but this was never replicated in a peer-reviewed Phase III trial, and the drug candidate was discontinued from the oral pharmaceutical pipeline in the early 2010s.

The subcutaneous peptide form used in compounding today is extrapolated from that animal and early human evidence. Direct evidence in women is absent from the published literature. This is an evidence gap you deserve to know plainly.

The Evidence Behind Each Agent: What We Actually Know

Tesamorelin's evidence base is stronger, though still limited in scope for off-label women's-health use. AOD-9604's human evidence is thin by any standard.

Tesamorelin RCT Data

The LIPO-010 and LIPO-011 trials are the foundational Phase III studies. Combined enrollment was approximately 800 adults; women made up roughly 15% of participants. At 26 weeks, tesamorelin 2 mg daily produced a statistically significant 18% reduction in VAT by CT scan versus 5% with placebo. Triglycerides fell by approximately 50 mg/dL in the treatment arm. The FDA label for Egrifta SV reflects these findings and sets the approved dose at 1 mg subcutaneous daily.

Critically, these trials were conducted in people with HIV on antiretroviral therapy, a metabolic context different from the perimenopausal weight gain or PCOS-related visceral adiposity most women asking about this peptide are dealing with. Extrapolating the VAT-reduction effect to those populations is reasonable mechanistically but is not directly supported by RCT evidence.

AOD-9604 Human Evidence

The most-cited human study is a 2001 dose-ranging study by Heffernan et al. in healthy obese adults, which tested oral AOD-9604 at doses from 1 mg to 30 mg. Subcutaneous fat loss was observed at 1 mg/day. No large-scale replication exists. There are no published placebo-controlled trials of subcutaneous AOD-9604 in women, in any life stage. Practitioner-reported outcomes circulating in the peptide community are anecdotal and subject to substantial selection bias.

The evidence gap here is real. Anything beyond the Heffernan pilot data involves significant extrapolation.

Sex-Specific Physiology: Why Being a Woman Changes the Calculation

The GH-IGF-1 axis behaves differently across a woman's life. During the reproductive years, estrogen amplifies GH secretion but reduces hepatic IGF-1 production per unit of GH. This means women in their 20s and 30s have higher GH pulse amplitude than men but lower IGF-1 for the same GH output, a phenomenon confirmed in sex-stratified GH physiology research published in the Journal of Clinical Endocrinology and Metabolism. The clinical implication: a given dose of tesamorelin may produce a larger GH pulse in a premenopausal woman with intact estrogen signaling, and a smaller IGF-1 response than the LIPO-010 male-majority population would suggest.

After menopause, estrogen loss reduces GH pulse amplitude and deepens visceral fat accumulation. Tesamorelin's mechanism is plausibly better suited to postmenopausal visceral adiposity than in the reproductive years, but this has not been tested in a dedicated RCT. The Menopause Society's 2022 position statement on body composition in menopause does not address GH-secretagogues or GHRH analogues, reflecting the absence of trial data in that population.

Menstrual Cycle Considerations

Tesamorelin's IGF-1-raising effect may interact with the follicular-to-luteal transition. IGF-1 acts as a co-gonadotropin in the ovary, supporting follicle growth and progesterone synthesis. Whether supraphysiologic IGF-1 from tesamorelin disrupts cycle regularity in women without HIV lipodystrophy is unknown. No published study has tracked menstrual cycle patterns during tesamorelin therapy in reproductive-age women. If you notice cycle changes after starting either peptide, that is a clinically meaningful signal worth reporting to your prescriber.

PCOS

Women with PCOS already have elevated androgen levels and often have altered GH pulsatility and IGF-1 signaling. One cross-sectional study in Fertility and Sterility found that lean women with PCOS had higher IGF-1 than body-mass-index-matched controls. Adding a GHRH analogue that raises IGF-1 further in this population raises theoretical concerns about androgenic signaling. There are no trials of tesamorelin in PCOS. AOD-9604, with its minimal IGF-1 effect, is arguably a lower-risk theoretical choice for women with PCOS and visceral fat concerns, but "lower theoretical risk" is not the same as "evidence-based recommendation."

Perimenopause and Postmenopause

Visceral fat gain accelerates during the menopausal transition, driven by falling estrogen and rising FSH. This is the life stage where interest in GH-axis peptides is highest among women seeking metabolic support. Tesamorelin's mechanism addresses one part of that physiology. A 2023 secondary analysis of GH-axis interventions in aging women, published in Menopause, noted that GH replacement studies in postmenopausal women show consistent but modest VAT reduction with large individual variability. Tesamorelin-specific data in this group does not exist at the RCT level.

When to Pick Tesamorelin Alone

Tesamorelin monotherapy is the better-supported choice when your primary goal is documented visceral adipose tissue reduction, particularly if you have metabolic syndrome features like elevated triglycerides and hepatic steatosis. The LIPO-010 data showed a 50 mg/dL triglyceride reduction over 26 weeks, a clinically meaningful effect in women with hypertriglyceridemia or non-alcoholic fatty liver disease.

Choose tesamorelin alone when:

• Your prescriber has ordered baseline and follow-up IGF-1 monitoring (essential for safety)
• You are postmenopausal with significant visceral adiposity and no hormone-sensitive tissue concerns
• You want the agent with the strongest clinical evidence, even if that evidence is from a different population
• You are unwilling to add a second compound with even weaker evidence

When to Pick AOD-9604 Alone

AOD-9604 alone is a consideration when you want to avoid IGF-1 elevation entirely. This includes women with a personal or family history of IGF-1-sensitive conditions, anyone uncomfortable adding a GHRH-stimulating agent while cycling, or practitioners who prefer starting with the agent that carries the lower theoretical hormonal disruption burden.

The trade-off is stark: you are accepting weaker evidence for a lower (theoretical) hormonal interaction risk. That is a reasonable individual choice if made with eyes open.

The Stack: When Combining Both Makes Sense, and When It Does Not

Stacking tesamorelin with AOD-9604 is based on mechanistic logic rather than RCT data. The proposed rationale is that tesamorelin raises GH pulsatility to reduce VAT through the IGF-1 pathway, while AOD-9604 acts on peripheral fat deposits through a separate lipolytic mechanism, offering complementary rather than redundant effects.

Practitioner-reported protocols typically combine:

• Tesamorelin 1 mg subcutaneous, administered in the evening to align with endogenous GH pulse timing
• AOD-9604 250-500 mcg subcutaneous, often dosed in the morning or pre-fasting window
• Cycle length of 12-20 weeks with a 4-8 week break, though no evidence supports any specific cycling interval

The stack may be reasonable to consider if:

• Tesamorelin monotherapy has been tolerated for at least 8-12 weeks with stable IGF-1 levels
• Your IGF-1 is not already at the upper limit of the age-adjusted reference range
• You have significant subcutaneous fat in addition to visceral fat (where AOD-9604's proposed lipolytic effect might add something)
• Your prescriber is monitoring fasting glucose, given that tesamorelin's transient insulin-sensitizing reduction could compound with any peripheral metabolic effect of AOD-9604

Do not stack if:

• You are in the trying-to-conceive window (both are contraindicated in pregnancy)
• Your IGF-1 is already elevated at baseline
• You have active cancer, a history of cancer, or active proliferative retinopathy
• You are on insulin or GLP-1 receptor agonists without your prescriber's active awareness, as GH-axis peptides can shift insulin requirements

Pregnancy, Lactation, and Contraception: Read This Before Starting Either Peptide

Tesamorelin is Pregnancy Category X. Animal studies showed fetal harm, and the GH-IGF-1 axis plays a direct role in placentation and fetal growth. There is no safe dose in pregnancy. The FDA label states tesamorelin is contraindicated in pregnant women, and this is not a situation where individual risk-benefit calculation changes that recommendation.

AOD-9604 has no human pregnancy safety data at all. Given its mechanism as a growth hormone fragment acting on fetal IGF-1 pathways, the precautionary position is that it is contraindicated in pregnancy. No guideline body has issued a formal statement, because no guideline body has evaluated it. Absence of data is not safety data.

Lactation: Neither agent has lactation transfer data in humans. Tesamorelin is a peptide (molecular weight approximately 5,136 Da) and would be expected to have limited oral bioavailability if transferred into breast milk, but measurable transfer cannot be ruled out. Given the theoretical risks to infant GH-axis physiology, neither agent should be used during breastfeeding. The LactMed database at NLM does not have a tesamorelin or AOD-9604 entry, which itself reflects the data vacuum.

Contraception requirement: Because tesamorelin is Category X and AOD-9604 has no pregnancy safety data, women of reproductive age should use reliable contraception throughout any course of either peptide. Barrier methods alone are not adequate. A hormonal method (oral contraceptive, IUD with hormones, implant) or copper IUD provides more reliable protection. Discuss your contraception plan with your prescriber before starting.

Trying to conceive: Stop both agents at least one full GH-axis cycle (suggested minimum 4-6 weeks) before any conception attempt, though no pharmacokinetic washout study defines this interval in women.

Who This Is Right For and Who Should Step Back by Life Stage

Reproductive-Age Women (Ages 18-40)

The risk-benefit calculation is most conservative here. Visceral adiposity in this group often has an underlying driver (PCOS, insulin resistance, hypothyroidism, or dietary pattern) that should be addressed first. GLP-1 receptor agonists like semaglutide have stronger RCT evidence for visceral fat reduction in metabolically unhealthy women. Tesamorelin or AOD-9604 may be considered only after those first-line options have been evaluated and reliable contraception is confirmed.

Perimenopausal Women (Ages 40-55)

This is the most common group asking about this stack in clinical practice. Menopausal hormone therapy (MHT) with estrogen remains the first-line intervention for menopause-related visceral fat accumulation, per NAMS 2022 position statement guidance. Peptides may be considered as adjuncts once MHT has been optimized, not as replacements.

Postmenopausal Women

The theoretical case for tesamorelin is strongest here, where GH pulsatility is lowest and visceral adiposity is highest. IGF-1 monitoring every 8-12 weeks is essential. Women with osteoporosis should note that GH-axis activation may have positive effects on bone turnover markers, but no fracture-endpoint data exists for tesamorelin in postmenopausal women.

Women With HIV-Associated Lipodystrophy

This is the only FDA-approved use. Tesamorelin 2 mg daily (Egrifta SV formulation) is indicated here. AOD-9604 stacking in this specific context has not been studied.

Monitoring Protocol for the Stack

Any prescriber offering this combination should have a monitoring plan. Based on tesamorelin's pharmacology and practitioner-reported protocols, a reasonable framework includes:

| Timepoint | Test | |-----------|------| | Baseline | IGF-1, fasting glucose, HbA1c, fasting lipids, LFTs | | Week 4 | IGF-1, fasting glucose | | Week 12 | Full panel repeat, symptom review | | Week 20-24 | End-of-cycle assessment, decision to continue, pause, or stop |

If IGF-1 exceeds the upper limit of the age-adjusted reference range at any point, the tesamorelin dose should be reduced or held. This is not optional. The FDA label specifies dose reduction if IGF-1 is persistently elevated above the reference range.

Practical Dosing Summary

Both peptides require subcutaneous injection. Tesamorelin must be reconstituted from lyophilized powder. AOD-9604 is typically supplied as a lyophilized powder for reconstitution with bacteriostatic water.

Evening dosing for tesamorelin is widely recommended in the peptide community because endogenous GH peaks in the first hours of sleep. The circadian biology of GH secretion supports this reasoning: injecting a GHRH analogue before sleep aligns the drug with your body's natural pulsatile rhythm rather than overriding it at a low-amplitude time.

AOD-9604 is often dosed in the morning, fasted, based on the rationale that lipolysis is highest in the fasting state. There is no published human pharmacokinetic study confirming that this timing matters for AOD-9604 specifically.

Rotate injection sites. Common sites include the lower abdomen and outer thigh. Lipohypertrophy from repeated injection at the same site can reduce absorption unpredictably.